Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PDGFR
    (10)
  • FGFR
    (3)
  • EGFR
    (2)
  • VEGFR
    (2)
  • Apoptosis
    (1)
  • CDK
    (1)
  • ERK
    (1)
  • FLT
    (1)
  • LPL Receptor
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

pdgf-receptor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    16
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • Recombinant Protein
    12
    TargetMol | Recombinant_Protein
CYM50260
T150311355026-60-6In house
CYM50260 is a potent and highly selective agonist of the sphingosine-1-phosphate 4 receptor (S1P4-R, EC50= nM), exhibiting no activity against S1P1-R, S1P2-R, S1P3-R, and S1P5-R.
  • Inquiry Price
6-8 weeks
Size
QTY
AG-494
Tyrphostin B48, AG 494, Tyrphostin AG-494
T4205133550-35-3
AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PDGFR Tyrosine Kinase Inhibitor III
PDGF Receptor Tyrosine Kinase Inhibitor III
T60108205254-94-0
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that inhibits PDGFR, EGFR, FGFR, PKA, and PKC and can be used for research on amyotrophic lateral sclerosis [1].
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Sale
KN1022
T60110205255-11-4
KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AG 1295
T1413771897-07-9
AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4].
  • Inquiry Price
Size
QTY
WQ-C-401
T2007662376694-72-1
WQ-C-401 is an orally active inhibitor of the platelet-derived growth factor receptor (PDGFR). It inhibits cell proliferation by blocking PDGFR auto-phosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRαY849 and 5.8 nM for PDGFRβY1021. Additionally, WQ-C-401 suppresses the proliferation and migration of PASMCs by inhibiting PDGF-BB-induced phosphorylation of ERK1 2, reduces collagen I synthesis, and increases α-SMA expression, thereby preventing pulmonary vascular remodeling. This compound shows promise for research in the field of pulmonary arterial hypertension.
  • Inquiry Price
6-8 weeks
Size
QTY
2-Methyl-3-phenylquinoxaline
T20151410130-23-1
2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).
  • Inquiry Price
10-14 weeks
Size
QTY
A-849529
A849529, A 849529
T201998819058-88-3
ABT-869 is an innovative ATP-competitive inhibitor targeting all vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases (RTKs). Its hydrophilic metabolite, A-849529, contains carboxyl and amino groups.
  • Inquiry Price
Size
QTY
ag-370
T21784134036-53-6
AG 370, an indole tyrphostin, is a potent inhibitor of PDGF-induced mitogenesis with an IC50 of 20 μM, and it shows weak inhibition of the EGF receptor.
  • Inquiry Price
6-8 weeks
Size
QTY
pd-161570
PD 161570
T23127192705-80-9
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. It also inhibits the PDGFR, EGFR, and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
  • Inquiry Price
Size
QTY
vegfr2 kinase inhibitor ii
T37079288144-20-7
Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. VEGFR2 kinase inhibitor II is a reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM). It less potently inhibits the platelet-derived growth factor receptor β (PDGFRβ; IC50 = 920 nM) and related receptor and non-receptor tyrosine kinases. VEGFR2 kinase inhibitor II blocks the growth of human umbilical vein endothelial cells stimulated with either VEGF or PDGF (IC50s = 110 nM and 2 μM, respectively).
  • Inquiry Price
6-8 weeks
Size
QTY
Ansornitinib
ANG3070, ANG-3070, ANG 3070
T638091448874-96-1
Ansornitinib (ANG-3070) is an orally active KDR and PDGF receptor inhibitor with antifibrotic activity that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2), and may be useful for the study of diseases caused by abnormal or excessive fibrosis.
  • Inquiry Price
6-8 weeks
Size
QTY
Tyrphostin AG1296
Tyrphostin AG 1296, AG 1296
T6711146535-11-7
Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
  • Inquiry Price
Size
QTY
CGP-53716
T67442152459-94-4
The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation[1]. CGP 53716 is a specific PDGFR tyrosine kinase inhibitor on SMC (smooth muscle cell) proliferation and migration in vitro and in neointimal formationin vivo[3]. CGP 53716 inhibited serum-induced cell growth in RASMC (rat aortic smooth muscle cells). And it completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μM in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μM in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. Further, CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. And it showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells[1]. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-α and PDGFR-β. After rat carotid artery ballooning injuryin vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg kg day of CGP 53716 from 38 ± 10 (control group) to 4 ± 2. Intima media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P=0.028) after rat aortic denudation[3].
    7-10 days
    Inquiry
    SU 5402
    SU5402
    T6996215543-92-3
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 values of 20 nM for VEGFR2, 30 nM for FGFR1, and 510 nM for PDGF-Rβ.
    • Inquiry Price
    Size
    QTY
    Rinucumab
    REGN2176, REGN 2176
    T768871569263-06-4
    Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGFreceptor and can be used to study age-related macular degeneration.
    • Inquiry Price
    Size
    QTY